Earnings call
Indoco Remedies Q2 FY26 earnings call: Indoco Remedies Limited is confident that its top line will be in the region of around INR3,500 crores in 3 years
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company is confident that its top line will be in the region of around INR3,500 crores in 3 years. Over the last 2 years, Indoco Remedies Limited invested heavily in its master manufacturing plant, remediation for Goa II, and major capex in its Warren subsidiary, where it has 2 separate units commissioned in Waluj, Sambhajinagar in Maharashtra. Stand-alone net revenues were INR4,293 million in the second quarter FY '25-'26, compared with INR3,946 million in the same quarter last year and INR3,856 million in the immediately preceding quarter, representing growth of 8.8% and 11.3%, respectively. The market on the ethical side of sensitivity expanded from INR500 crores to INR700 crores in the last 4 years. The sale and leaseback transaction was completed in 2 lots totalling very close to INR50 crores.
The numbers management gave
Results
- Stand-alone net revenues were INR4,293 million in the second quarter FY '25-'26, compared with INR3,946 million in the same quarter last year and INR3,856 million in the immediately preceding quarter, representing growth of 8.8% and 11.3%, respectively.
Show source
Stand-alone net revenues of the company for the second quarter FY '25-'26 are at INR4,293 million compared to INR3,946 million for the same quarter last year and INR3,856 million for the immediately preceding quarter.
- Consolidated net revenues were INR4,718 million in the second quarter, compared with INR4,307 million in the same quarter last year and INR4,309 million in the immediately preceding quarter, representing growth of 9.6% and 9.5%, respectively.
Show source
Consolidated net revenues of the company for the second quarter are at INR4,718 million compared to INR4,307 million for the same quarter last year and INR4,309 million for the immediately preceding quarter, giving 9.6% and 9.5% growth, respectively.
- Stand-alone EBITDA to net sales was 12.4% at INR534 million in the quarter, compared with 13.4% at INR529 million in the same quarter last year and 3.8% at INR148 million in the immediately preceding quarter.
Show source
Stand-alone EBITDA to net sales for the quarter is 12.4% at INR534 million compared to 13.4% at INR529 million same quarter last year.
- Consolidated EBITDA to net sales was 9.1% at INR431 million in the quarter, compared with 9.3% at INR403 million in the same quarter last year and 4.1% at INR175 million in the immediately preceding quarter.
Show source
Consolidated EBITDA to net sales for the quarter is 9.1% at INR431 million compared to 9.3% at INR403 million and for the immediately preceding quarter, 4.1% at INR175 million.
- Domestic formulation business revenues were INR2,261 million for the quarter, compared with INR2,346 million.
Show source
Revenues from domestic formulation business for the quarter are at INR2,261 million compared to INR2,346 million.
- International formulation business revenues were INR1,533 million, compared with INR1,262 million, in Q2 FY '26.
Show source
On the international formulation business front, revenues from international formulations are at INR1,533 million compared to INR1,262 million.
Show 24 more statements
Results
- Reg markets revenues were INR915 million for the quarter, compared with INR866 million.
Show source
Revenues from reg markets for the quarter are at INR915 million as against INR866 million.
- U.S. business revenues were INR336 million for the quarter, compared with INR247 million.
Show source
Page 3 of 18 Indoco Remedies Limited November 06, 2025 Revenues from U.S. business for the quarter are INR336 million as against INR247 million.
- Europe revenues were INR547 million for the quarter, compared with INR599 million.
Show source
From Europe, for the quarter, the revenues stand at INR547 million as against INR599 million.
- Revenues from South Africa, Australia and New Zealand were INR33 million, compared with INR20 million, in Q2 FY '26.
Show source
And for South Africa, Australia and New Zealand, they are at INR33 million as against INR20 million.
- Emerging markets revenues were INR618 million, compared with INR396 million, and its API business revenues were INR431 million, compared with INR301 million, in Q2 FY '26.
Show source
Revenues from emerging markets for the quarter are at INR618 million against INR396 million, and revenues for the API business for the quarter are INR431 million against INR301 million.
- AnaCipher CRO and Indoco Analytical Solutions revenues were INR68 million, compared with INR37 million, in Q2 FY '26.
Show source
Revenues from AnaCipher CRO and Indoco Analytical Solutions are at INR68 million against INR37 million.
- Other expenses include remediation costs related to the USFDA remediation at Plant 2, which are likely to continue for another 2 quarters.
Show source
And these specifically are likely to go on for another 2 quarters.
- Warren's API growth, which was almost 40% quarter-on-quarter and year-on-year, was partly contributed by the Warren subsidiary.
Show source
And if you see the API uptick, the current growth in our API, which is almost about 40%, you can see quarter-on- quarter as well as even Y-on-Y basis, some portion is contributed by this particular subsidiary called Warren.
- The company generated cash from operating activities in Q2 FY '26 that was almost equal to what it generated during last 1 year.
Show source
Quarter 2, we have generated cash from operating activities that is almost equal to what we generated during last 1 year.
- Europe business did INR118 crores in the first half and was in a run rate of INR230 crores, INR250 crores already, because manufacturing challenges continued in the first quarter this year.
Show source
So we are in that run rate of INR230 crores, INR250 crores already.
- Around INR4 crores came from API in Warren Remedies' top line this quarter.
Show source
I think around INR4 crores came from API in the Warren Remedies top line this quarter, but let me just quickly check it.
- Warren Remedies had INR34 crore revenue this quarter, of which almost INR29 crores came from OTC sales.
Show source
So coming back to this quarter, I think of the INR34 crore revenue, we have almost INR29 crores coming from OTC sales.
- Warren Remedies had INR71 crores revenue for the first half, of which INR61 crores came from OTC sales.
Show source
For the first half, of the INR71 crores, INR61 crores has come from OTC sales.
- The company made close to INR63 crores, INR64 crores in Europe in quarter 1 of the current financial year and INR55 crores in Q2.
Show source
And Q2, we made INR55 crores.
- Sales promotion expenses have gone up because the first half of the year is typically a period when it does not hold campaigns, CMEs and other product-related activities such as samples.
Show source
Page 4 of 18 Indoco Remedies Limited November 06, 2025 Also, our sales promotion expenses have gone up requisite to the -- since typically, for the first half of the year, we do not hold anything here.
- Cyclopam and Cital products remained impacted because hot, moist summers and excessive heat without moisture did not occur this year.
Show source
Both these products stay impacted.
- Despite headwinds for Cyclopam and Cital, Indoco Remedies Limited performed well with Oxipod, Fabrex Plus, Karvol Plus and some of its ATM products.
Show source
So despite headwinds for Cyclopam and Cital because of very good performance by Oxipod, which is an antibiotic, Fabrex Plus, which is anti-cold, Karvol Plus, which is also anticold and some of our ATM, which is an antibiotic, the company Page 8 of 18 Indoco Remedies Limited November 06, 2025 has managed to show a decent performance.
- Major therapeutic segments, including vitamins, anti-diabetics, anti-infectives and respiratory, performed well during the quarter compared with the same quarter last year. Replaced by a later filing.
Show source
Major therapeutic segments like vitamins, anti-diabetics, anti-infectives and respiratory performed well during the quarter as compared to the same quarter last year.
- Recurring other expenses, including lab expenses, spares and other plant-related efficiency expenses, are coming under control. Replaced by a later filing.
Show source
So the recurring kind of other expenses, in fact, are being very well brought under contr ol, such as lab expenses, your spares and all the other plant -related efficiency related, those are coming under control.
Money and capital
- The sale and leaseback transaction was completed in 2 lots totalling very close to INR50 crores.
Show source
Pramod Ghorpade: No, no, no. In 2 lots, it was done totalling to very close to INR50 crores.
- Commitment to repay loans in the second half of this particular year is close to about INR52 crores.
Show source
And our commitment to repay in the next half, that is the second half of this particular year is close to about INR52 crores.
- Commitment to repay loans a year after this particular year is close to about INR140 crores.
Show source
And a year after that, close to about INR140 crores.
- The company would do maintenance capex in the region of around INR50 crores to INR70 crores max, with INR50 crores because it has several sites.
Show source
Page 16 of 18 Indoco Remedies Limited November 06, 2025 Aditi Panandikar: We would do more of maintenance capex in the region of around INR50 crores to INR70 crores max, INR50 crores because we have several sites.
- The company repaid certain loan in first half of this particular year. Replaced by a later filing.
Show source
This year itself, we repaid certain loan in first half.
What it expects ahead
What management expects
- After a U.S. FDA audit, if everything goes fine in a clean quarter, Indoco Remedies Limited expects INR30 crores incremental.
Show source
So in a clean quarter after U.S. FDA audit with everything going fine, we can definitely expect INR30 crores incremental.
- The company is confident that its top line will be in the region of around INR3,500 crores in 3 years.
Show source
From here in 3 years, I feel confident to be in the region of around INR3,500 crores.
- WRPL and FPP will continue to bleed a bit for another 2 quarters, while WRPL's performance depends on how fast OTC sales grow during a period of investment.
Show source
So we should look at another 2 quarters where these 2 subsidiaries will continue to bleed a bit.
- The company expects R&D to come down from around 5% of sales to 4% in the very first year as sales pick up, through greater R&D efficiency, work on products with vertically integrated API, and mindfulness about parallel projects and Para IV opportunities.
Show source
But as the sales pick up, I think we should -- going forward, we can bring it easily down to 4% in the very first year.
- The company expects to show double-digit growth in its Europe, U.K. business from here on.
Show source
So I expect that at least from here on, we should be able to show a double - digit growth in Europe, U.K. business.
- From Q3 onwards, Indoco Remedies Limited expects sales promotion expenses to slow down if the India business is not delivering the returns it needs.
Show source
And generally, if we see that the India business is not giving us, for example, the kind of returns that we need, then accordingly, from Q3 onwards, you will see them slowing down.
Show 5 more statements
What management expects
- The company hopes to sell more solid orals to generate additional U.S. revenues before the U.S. FDA audit.
Show source
Till then, we hope we will be able to sell more of our solid orals so that we can get some more revenues for U.S. Madhav: That answers my question.
- The company is confident it will show higher single-digit growth in its India business in the quarters to come.
Show source
I'm confident that we will be able to show a higher single-digit growth in India business in the quarters to come as well.
- After completing the API manufacturing facility and obtaining approval, Warren will start the product, which is expected to provide a better margin from the plant.
Show source
Once we finish this API manufacturing facility and go for approval, then we'll start the product, which will give us a margin -- better margin from this particular plant.
- The company is confident that Warren will soon achieve positive margins.
Show source
And we are very confident that we'll very soon come into positive margins from this particular entity.
- The company is not currently seeing in Europe the same level of opportunity for sterile products as in the U.S.; Europe would be a backup strategy for U.S. challenges unless it works with a very large partner that already has market share and becomes a contract manufacturer.
Show source
So Europe, unless we work with a very large partner who already has a market share and become the contract manufacturer or something like that, which defeats the purpose, it would be a backup strategy for U.S. challenges, I would say.
What it is building and selling
Projects and capacity
- Over the last 2 years, Indoco Remedies Limited invested heavily in its master manufacturing plant, remediation for Goa II, and major capex in its Warren subsidiary, where it has 2 separate units commissioned in Waluj, Sambhajinagar in Maharashtra.
Show source
So these are major capex which we carried during last 2 years.
- The company does not expect any further specific capex for at least the next few years because it has capacity available to utilize.
Show source
Now there is no any further specific capex, which is required for at least next few years because we have now a good amount of capacity which is available to utilize.
- The company has no capex planned except running capex.
Show source
No capex as such, except running capex.
- Warren Remedies depends on the Patalganga site and will become a second site for regulated API.
Show source
So it will become a second site for regulated API.
Demand and pricing
- The market on the ethical side of sensitivity expanded from INR500 crores to INR700 crores in the last 4 years.
Show source
And just to tell you why this was necessary, I said it in earlier calls and you must know it that on the ethical side of sensitivity, the market only expanded in the last 4 years from INR500 crores to INR700 crores.
- The market beyond X had a doubling up of market size. Replaced by a later filing.
Show source
But on the other side, which is beyond X, there has been an expansion, which is like doubling up of market size.
Show 2 more statements
Segments
- The company is trying to derisk by getting its larger products approved at facilities outside its own, from other CMOs, rather than investing further on U.S.
Show source
Aditi Panandikar: So what we are doing at this stage is we are trying to derisk from our side by getting our larger products approved and approved in other facilities outside of our own from other CMOs.
- Warren Remedies is currently remaining in OTC, frankly restricted to Oral Care.
Show source
Aditi Panandikar: No. Right now, we are remaining in OTC, frank OTC restricted to Oral Care.
Risks, rules and outside factors
Rules and policy
- The company has an approval from Europe for some very promising products it had filed.
Show source
Aditi Panandikar: So we have an approval from Europe because we had filed some very promising products.
Everything else said on the call
Group structure
- Warren Remedies' API is a support system for parent Indoco, as Indoco's API division was able to sell high volumes going forward and needed expansion of key starting material manufacturing areas.
Show source
API is only a support system for the parent Indoco because we saw our API division being able to sell high volumes going forward and needed an expansion of the key starting material manufacturing areas.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Madhur Rathi: Is it higher than 20% on an EBITDA level or even higher than 20%, 25%...
Answer, aditi panandikar
Aditi Panandikar: Yes, I think your numbers are quite ballpark.
Question
Madhur Rathi: Okay. And at what rate do we see this business growing either by new product additions or just taking market share from different players over the next 2 to 3 years?
Answer, aditi panandikar
Aditi Panandikar: So even now, if you have checked then on a consolidated basis, we have grown by 11% in India, which is way above the IPM and the covered market growth of around 8% -- 7%, 8%. This is despite we have a heavy seasonal portfolio. And Cyclopam, one of our main brands, although on a MAT basis, it is growing at 12%. The prescriptions are growing by 12% and the product is also growing. This year because the rains have come early and they refuse to go away. I mean probably this is the longest monsoon we've had in the last decade. So it is doing a bit of a flip flop for some of our acute products.
Answer, aditi panandikar
So Cyclopam, which is typically anti-spasmodic, which gets -- which sells a lot when there is food-related diarrhea, which happens when there are hot moist summers, which did not happen this year as well as Cital, which is like a urinary alkalizer, which also sells very well when the heat is excessive and there is no moisture. Both these products stay impacted. So despite headwinds for Cyclopam and Cital because of very good performance by Oxipod, which is an antibiotic, Fabrex Plus, which is anti-cold, Karvol Plus, which is also anticold and some of our ATM, which is an antibiotic, the company Page 8 of 18 Indoco Remedies Limited November 06, 2025 has managed to show a decent performance. I'm confident that we will be able to show a higher single-digit growth in India business in the quarters to come as well.
Question
Madhur Rathi: Got it. And ma'am, can you please mention about the new product addition strategy? Or how are we making our portfolio more resilient towards these cyclical ups and downs?
Answer, aditi panandikar
Aditi Panandikar: Yes. So yes, we have launched 2 antibiotics this quarter also. But if you look at overall our new launches, then we have products across almost all segments because we have 5 or 6 divisions and each division takes new launches. So we have new launches in urology. We have done an extension of the Cital portfolio to make it a little unseasonal. So Cital primary brand is highly dependent on heat and summer season. But Cital UTI, which is for urinary tract infection.
Answer, aditi panandikar
And the new launch, Cital PM6 solution in urology. It is a potassium salt of the same sodium citrate. So it is unseasonal. Dropizin cough syrup in Spade, which we launched, it is again, for cough and for -- when there was a prolonged COVID. So it is not necessarily related to the season. Another GI product we have launched is Drotitec, which is another anti-spasmodic. This is to expand our antis-spasmodic portfolio.
Answer, aditi panandikar
We have launched a new Macuchek in ophthalmology, which is a multivitamin product in -- for ophthalm for degenerative -- age-related degenerative ophthalmic illness. We have another product in stomatological, which we have launched is Rinseoff mouthwash and gargle. This is a very good product and has done quite well after launch also because given the kind of respiratory ailments we are seeing now post COVID, where there is a whole lot of throat pain and dry cough and mucus and people are looking at beyond antibiotics and beyond cough syrups for treatment. In addition to that, we have done a brand extension of our old brand, Weppl by launching Weppl CV, which is with clavulanic acid cefpodoxime. And another product, Vopanza, which we have launched is voriconazole, which is your -- PPI, sorry. And then we have Tuspel AA, which I talked of and multiple. So we are doing launches across a variety of segments.
Answer, aditi panandikar
Most of these fall in the subchronic kind of product therapy area.
Answer, aditi panandikar
Aditi Panandikar: Yes. I'll let my CFO answer that technically to you. Page 9 of 18 Indoco Remedies Limited November 06, 2025 Pramod Ghorpade: So Mr. Sajal, thanks for this question.
Answer, pramod ghorpade
So this gives us an opportunity to explain you about these 2 subsidiaries. One is about the FPP. So a couple of years back, we got this subsidiary in U.S. Advantages they have licenses to operate in all states in U.S. And we started shipping certain goods. So now with our sterile plant under regulatory constraint, we could not supply as many products as we wanted to. So our plan is to now -- once we resume production and once we are out of this regulatory challenges, we will supply those, and they will act as a front end for us where that is a bigger plan for APP. And we are very confident that we should turn around this very quickly. If you see the overall expenses for the FPP, those are really controlled very well.
Answer, pramod ghorpade
We have only 6 people operating there in U.S. We don't have much overheads as such, except rent and salaries for the 6 people. The second subsidiary, which you talked about WRPL, the Warren remedies. In Warren remedies, there are 2 part of business. One is the OTC business, which launched last year. And second one is API intermediates and API finished goods. So out of these 2, OTC, we launched, we have a manufacturing setup under this particular entity, which started -- which is commissioned and started delivery. In all right from commissioning, we could manufacture close to about 92 lakhs tubes till date from that particular plant, which is a highly automated plant, which is supporting for our OTC venture.
Answer, pramod ghorpade
That is one. Second phase, which is about API, where intermediate plant has started and it started supplying to our Patalganga plant. But the API finished goods will be closed very soon. And if you see the API uptick, the current growth in our API, which is almost about 40%, you can see quarter-on- quarter as well as even Y-on-Y basis, some portion is contributed by this particular subsidiary called Warren. Once we finish this API manufacturing facility and go for approval, then we'll start the product, which will give us a margin -- better margin from this particular plant. So we have very specific assumptions, which is very specific strategic plan for this particular entity. And we are very confident that we'll very soon come into positive margins from this particular entity.
Question
Sajal Kapoor: Sure, sure. And while we are on this balance sheet and if I can just quickly check what the thought process is currently on the rising debt profile on the balance sheet? Because if I look at our business over the last 10 years, roughly speaking, our -- over the last 10 years, our sales have barely doubled. But our interest payment has gone up tenfold. So we used to be running at INR10 crores, INR11 crores of annual interest cost. Today, we are approaching INR100 crores run rate quarterly '24, 25, right? I mean this is clearly not sustainable. So what is -- I mean, operating cash flow yes, we got to do innovation. We got to do R&D. We got to do plant upgradation, remediation cha
Answer, pramod ghorpade
Pramod Ghorpade: Yes. So Mr. Sajal, so if you remember our past calls, so last about 2 years, we have invested heavily on -- particularly on the master manufacturing plant, that is one. And secondly, on remediation for Goa II. In addition to this, major capex is invested in this Warren subsidiary, where we have now 2 separate units. Which are commissioned in Waluj, Sambhajinagar in Maharashtra. So these are major capex which we carried during last 2 years. Now there is no any further specific capex, which is required for at least next few years because we have now a good amount of capacity which is available to utilize.
Answer, pramod ghorpade
We have done a lot of projects on increasing the efficiency in particularly in Baddi I, Baddi II and Goa I, our plant. So that should give us a decent margins. That will increase our overall capex -- overall cash flow. Secondly, we have reduced our R&D spend. So we have been very clear in terms of controlling the R&D spend as such because we have multiple products which are either approved or in process of approval, which should give us a good amount of overall product portfolio going forward for next 2 to 3 years. So we expect to reduce a little bit of R&D spend. No capex as such, except running capex.
Answer, pramod ghorpade
And as regards to expansion in our margin, that will increase our overall cash inflow. We can see that in quarter 2 also. Quarter 2, we have generated cash from operating activities that is almost equal to what we generated during last 1 year. So you can see that, and we anticipate to make -- start repaying. This year itself, we repaid certain loan in first half. And our commitment to repay in the next half, that is the second half of this particular year is close to about INR52 crores. And a year after that, close to about INR140 crores.
Answer, pramod ghorpade
So we are definitely confident in terms of generating that much cash flow, including supporting for the finance. So Madam...
Answer, aditi panandikar
Aditi Panandikar: Yes. I just wanted to add something. So for this decade of investment, I agree with you. We also have moved models for our regulated markets and moved from being a pure contract manufacturer to sort of front ending in both the geographies, whether it is U.K. or Europe and in fact, even in Germany with our own MAs, etc. This has been a transition because we did realize that with the kind of infrastructure investment required to succeed in these markets. If we remain only a sort of benign player with having no say in exactly when our products would get launched with an inability to, therefore, convert opportunities into gains, we really suffered because otherwise, we had a great ophthal portfolio, which should have today been of a very different size. So that has meant that our milestone collections from the likes of Teva are very minimal now, almost nothing. And instead, we have paid them back whatever we had collected to own all these assets.
Answer, aditi panandikar
It simply means that going forward, much of the investments that were to be done towards U.S. as a business, towards Europe as a business are done and over with. Page 11 of 18 Indoco Remedies Limited November 06, 2025 And from here on, we have to only manufacture and convert it to sales and get the opportunity. We are instead investing towards the OTC business, which we see has a great promise in India. And it is required for how the market conditions for the Indian business are ripe for this kind of change in -- not exactly change, but a kind of a lateral increment for where we are. So beyond doing pure ethical, we are also going to OTC. So you will see the organization shape a little differently going forward. And I give you confidence that the kind of capex we have done or the kind of R&D budgets you have seen historically when we work with large players, those are not going to happen in the years and to come.
Answer, aditi panandikar
But our pipeline is not going to dry because we have, over the last 5 years, invested in products, which will be commercialized from '28 onwards. So we have enough product to support us for growth. I hope that answers your question.
Question
Sajal Kapoor: Yes, it helps, Aditi ma'am. And strategy-wise, I think it makes sense to own our future, own our IP in our hands and then commercialize them, taking the majority or all of the gains, but we have taken certain risk, i.e., piling the debt on the balance sheet. Now our aspiration at one point in time a couple of years back was to get to this target of INR5,000 crores of top line, give or take. How realistically -- yes, and what is your kind of -- given what has happened and the remediation of Goa Plant II, Line 1 and so on, what is your realistic expectation over the next 3 years? Let's not talk about next year because we'll still be probably in a ramp-up mode after the U.S. FDA a
Answer, aditi panandikar
Aditi Panandikar: So yes, thank you for that question, and thank you for understanding the hell we have gone through. So the loss of opportunity has really hurt us tremendously. And we realized that, as you correctly said, we must own the chain through and through. So yes, because of all that we've gone through in the last couple of years, the INR5,000 crore in 2027, which was our immediate agenda, looks a little bit distant at this stage. I feel that we will have to take a delay of probably 18 months to realize that beyond 2027. That is only for the top line, though. The margin improvement, you will see substantial.
Answer, aditi panandikar
I'll give you a little flavor of what's going on. Like I said, for Europe, which is our largest volume business outside of India, because of the MMP investments, we will see much better EBITDA returns in the quarters to come. In emerging markets where we are focusing with on-ground people and where we participate only with the branded business and where we are now giving more focus, you will see much better growth. And these markets give EBITDA close to India business kind of. In India, where we are not growing or increasing the number of people on the ground, rather focusing on getting more from the metros where sales are coming more incrementally and doing much better with our new launches. I expect the Indian business to give us better return. The only one business where I will have to support for the next 3 or 4 years with expenditure for creating brands will be the OTC.
Answer, aditi panandikar
Page 12 of 18 Indoco Remedies Limited November 06, 2025 So I feel confident that going forward -- you asked me a picture of 3 years. Today, last year, we did INR1,500 roughly crores with a degrowth. From here in 3 years, I feel confident to be in the region of around INR3,500 crores.
Answer, aditi panandikar
Aditi Panandikar: Yes. So I'll answer the second part first. For FPP, it really doesn't matter where we give the product from. They are a sales and distribution company kind of, although they are our front end. And they take orders for the product, not irrespective of where it is made. It has to be against our ANDA, of course. So coming back to, yes, I mean, it should not happen, but supposing we have challenges with the FDA, both in terms of the time of the audit or the outcome.
Answer, aditi panandikar
Yes, the products that are currently approved and in the market, we have been proactively working on this now for an entire year. So some products we will be immediately able to put into the market. Others which are under approval from U.S. FDA, however, or where we are making changes because the new sites have kind of an equipment or which is different, which requires a change in process, we may have to wait a little bit for the regulator to approve it. So it will be a mixed bag, but we will definitely -- even then we will be doing better than we did in H2 when we were at absolute lows because our solid oral supplies are going very well. Glimipiride, an antidiabetic, which we are supplying to U.S. is doing very well. We are vertically integrated on this product. Another product, Allopurinol, which we are vertically integrated on is also doing decently all right in U.S. And I feel that the solid oral portfolio will continue to give us a good top line from U.S. and growth because in the second half of last year, our U.S. supplies of solid oral had also got impacted.
Answer, aditi panandikar
So from a growth perspective, we will do well. From an opportunity perspective on ophthalmics, if the U.S. FDA does not clear us sight, yes, we will not be able to deliver like we expected, but it will not come to an absolute 0.
Question
Dhwanil Desai: Okay. Got it. Second question on Europe. So I think you talked about double-digit growth from the current run rate of INR55-odd crores on this quarter. But going back a couple of years back, we were kind of INR300 crore plus on the Europe side of it. So on a run rate basis, by Q4, should we be able to reach that number? What are your thoughts on kind of reaching that milestone of INR300 crores on the Europe side?
Answer, aditi panandikar
Aditi Panandikar: Yes. Actually, by next year itself, we should be able to do it. This year, in the first half, we have done INR55 crores from Europe... Page 13 of 18 Indoco Remedies Limited November 06, 2025 Pramod Ghorpade: INR118 crores.
Answer, aditi panandikar
Aditi Panandikar: INR118 crores, sorry. This is Q2. I'm sorry. Yes. First half, we've done INR118 crores already. So we are in that run rate of INR230 crores, INR250 crores already. And this is simply because first quarter this year, we -- our manufacturing challenges continue.
Answer, aditi panandikar
So it will be a full year with 1 quarter not giving optimal. So next year itself, I think we should be able to do your -- the number that you have talked of, 100%, if not more.
Question
Dhwanil Desai: Okay. Second question on the consol numbers. I think at subsidiary level, there is significant increase in loss on a sequential basis. So I assume that will be largely from the OTC side, right, because FPP operations are almost stagnant… Aditi Panandikar: Yes, yes.
Answer, aditi panandikar
I think Pramod explained it earlier, what you heard. So it is largely from the OTC business because we have restarted our promotions.
Question
Dhwanil Desai: Okay. So how should we look at this number? Is this the run rate now going forward, at least for this H2? And I think we talked about a couple of years before we break even on the OTC side. So...
Answer, aditi panandikar
Aditi Panandikar: On FPP, I'm far more confident we'll be able to recover losses more quickly. And in a couple of quarters, FPP should be able to break even. But WRPL, it is really a function of how fast we can grow the sales in OTC because there will be a period of investment. So we should look at another 2 quarters where these 2 subsidiaries will continue to bleed a bit.
Question
Dhwanil Desai: Okay. By any chance, ma'am, can you give a number of sales number at which we would break even rather than a time line? Is that possible?
Answer, aditi panandikar
Aditi Panandikar: So as Pramod explained earlier, the WRPL of Warren Remedies Private Limited is a consolidation of 2 strategies for the company. One is to manufacture and sell cosmetic toothpaste and other oral products. And the second is to support Indoco Remedies' API strategy. So at this stage, I see that the OTC side of business will break even much faster despite of the investment we do, simply because the API manufacturing, which is currently only making key starting materials, the finished product construction is underway. That will get completed, after which we will file with U.S. FDA, after which the site will be triggered and then we'll be able to sell finished API from that site. So there will be a lag on the API side for breaking even. But we keep our fingers crossed for the OTC side doing so well in sales that it should help the whole entity breakeven faster.
Question
Dhwanil Desai: Okay. And 2 questions on the number side. So Pramod, sir, the other operating income has gone up significantly. So can you help us understand what that number contains?
Answer, pramod ghorpade
Pramod Ghorpade: Yes. So there are 2 components. One is foreign exchange gain, looking at dollar, euro and GDP rate, you can understand there is a good amount of gain. And second is the exports incentives, which we could realize during this time. Since exports are increased as compared to previous couple of quarters, there is a contribution of exports incentive in that particular number. Page 14 of 18 Indoco Remedies Limited November 06, 2025 Dhwanil Desai: Okay.
Show 1 more question
Question
Got it. And on the R&D side, ma'am, you and Pramod sir, both mentioned that going forward, R&D cost probably will kind of come down a bit. So any sense on the number that you can give?
Answer, aditi panandikar
Aditi Panandikar: So we have been hovering at around 5% of our sales. But as the sales pick up, I think we should -- going forward, we can bring it easily down to 4% in the very first year. And this is not because our focus on R&D is going away. We are just being a little bit more mindful on the kind of efficiency R&D can give us. So we are looking at working more on products where we are vertically integrated on API so that we don't spend too much on the material that goes into taking these batches. We have been mindful of how many projects we take up parallelly. We have been mindful of how many Para IV like opportunities we don't wish to go into, where we are ready with product way before we can -- for example, I can say that openly now because we just got a tentative approval on the Canagliflozin.
Answer, aditi panandikar
Aditi Panandikar: So we are not doing that. But I'll tell you very honestly, you know logically that products that have taken OTC have to start with very good GCs. Otherwise, it's impossible to even survive or stand because these products in the initial years, when you take them from X to C, need a whole lot of support with advertising budgets, etc. So you don't be concerned about that. The products as such are really profitable even at GC level, at EBITDA level, but the kind of support they need initially for the company to register and for us to make that shift from beyond selling at chemists to selling at grocers, selling through modern trade and to reach the consumer, the initial years are going to be a bit draining on the margin. Naysar: Okay. And ma'am, what would be the -- because since Warren Remedies has 2 businesses, OTC and API intermediates, OTC contribution would be how much in this quarter? Page 15 of 18 Indoco Remedies Limited November 06, 2025 Aditi Panandikar: On topline perspective, OTC would be 98% of the revenue.
Answer, aditi panandikar
No, I'm sorry. This year, we did a little better on API because API currently makes KSMs, which get transferred to our Patalganga site. If somebody can upload that. I think around INR4 crores came from API in the Warren Remedies top line this quarter, but let me just quickly check it. Naysar: And maybe on the OTC side, your portfolio will be restricted to Oral Care or maybe you would look to expand other categories? And if yes, when...
Answer, aditi panandikar
Aditi Panandikar: No. Right now, we are remaining in OTC, frank OTC restricted to Oral Care. I don't think you guys want me to put more money behind advertising. Let me stick to one area and perform. And just to tell you why this was necessary, I said it in earlier calls and you must know it that on the ethical side of sensitivity, the market only expanded in the last 4 years from INR500 crores to INR700 crores. But on the other side, which is beyond X, there has been an expansion, which is like doubling up of market size. So we had to go after this opportunity. And that is what OTC gives you.
Answer, aditi panandikar
It may not give you the same margin profile as ethical, but it will give you a huge opportunity of creating brand, and it is very much required for us to do that. So coming back to this quarter, I think of the INR34 crore revenue, we have almost INR29 crores coming from OTC sales. For the first half, of the INR71 crores, INR61 crores has come from OTC sales. So it is very much an OTC company, okay? API is only a support system for the parent Indoco because we saw our API division being able to sell high volumes going forward and needed an expansion of the key starting material manufacturing areas. And as such, today, we depend on the Patalganga site. So it will become a second site for regulated API.
Answer, aditi panandikar
Yes. Go ahead. You were asking the question. Naysar: Yes. Overall Warren Remedies, you think that maybe you said next 2 quarters, we will still be loss-making. But FY '27, you think you can break even at PAT level in Warren Remedies?
Answer, aditi panandikar
Naysar: Okay. And since you have done a very large capex last 2 years and capex requirement is minimum. So for, let's say, next 2, 3 years, what could be the capex roughly, if you can just indicate? Page 16 of 18 Indoco Remedies Limited November 06, 2025 Aditi Panandikar: We would do more of maintenance capex in the region of around INR50 crores to INR70 crores max, INR50 crores because we have several sites.
Answer, aditi panandikar
Aditi Panandikar: So we have an approval from Europe because we had filed some very promising products. But I'll be very honest, the kind of opportunity the sterile products have in U.S. Currently, we are not seeing that too much in Europe. So Europe, unless we work with a very large partner who already has a market share and become the contract manufacturer or something like that, which defeats the purpose, it would be a backup strategy for U.S. challenges, I would say. Madhav: Okay. And any reason madam for the -- if you compare the quarter 1 and quarter 2 for the Europe. So quarter 1, I think we have made close to INR63 crores, INR64 crores in the current financial year. And Q2, we made INR55 crores.
Answer, aditi panandikar
Madhav: Okay. And last query again on the Clarity Pharma segment. Out of the 15 products for the Clarity Pharma, so all 15 products are new products, and no existing product is available for the Clarity Pharma for distribution.
Questions about this call
- When was the Indoco Remedies Q2 FY26 earnings call transcript filed?
- Indoco Remedies filed the transcript with the exchange on 10 Nov 2025. This page is built from that transcript.
- What does this page list?
- 51 statements from the transcript across 8 topics, 19 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 11 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.